1334607-75-8

Basic information

• Product Name: 4-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-5-pyrimidinyl)-2-ethylphenyl]oxy}butanoic acid
• Synonyms: 4-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-5-pyrimidinyl)-2-ethylphenyl]oxy}butanoic acid
• CAS NO: 1334607-75-8
• Molecular Weight: 454.953
• Mol File: 1334607-75-8.mol

Chemical Properties

• CAS DataBase Reference: 4-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-5-pyrimidinyl)-2-ethylphenyl]oxy}butanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-5-pyrimidinyl)-2-ethylphenyl]oxy}butanoic acid(1334607-75-8)
• EPA Substance Registry System: 4-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-5-pyrimidinyl)-2-ethylphenyl]oxy}butanoic acid(1334607-75-8)

Safety Data

• Hazardous Substances Data: 1334607-75-8(Hazardous Substances Data)

Upstream product

• 1334608-21-7 ethyl 4-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-5-pyrimidinyl)-2-ethylphenyl]oxy}butanoate 
• 1334608-01-3 5-bromo-2-(3-chloro-4-isopropoxy-phenyl)-pyrimidine 
• 1334608-20-6 ethyl 4-{[2-ethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]oxy}butanoate 
• 3964-56-5 4-bromo-2-chlorophenol 
• 1260023-79-7 2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 201849-21-0 4-bromo-2-chloro-1-[(1-methylethyl)oxy]benzene 

Relevant articles and documents

PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Disclosed are pyrimidine derivatives for use as a sphingosine 1-phosphate 1 (S1P1) receptor agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or diseases mediated by S1P1 receptors, particularly multiple sclerosis.

PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Disclosed are pyrimidine derivatives for use as sphingosine 1- phosphate 1 (S1P1) receptor agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or diseases mediated by S1P1 receptors, particularly multiple sclerosis.